Science

DNA nanoswitches find new drug leads faster by measuring protein interactions

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 05/11/2026, 19:10:24 UTC.

Briefings

Researchers at Harvard University developed FIND, a drug discovery platform using DNA nanoswitches to identify molecules that modulate protein interactions rather than just binding to a single target. This approach allows the system to screen large libraries for effective drug candidates more efficiently than traditional methods. The study was published in 2026, and the platform aims to accelerate the identification of new therapeutic leads.

Key points

• The FIND platform uses DNA nanoswitches to select drug candidates based on their effects on protein-protein interactions, distinguishing it from conventional binding-based screening methods.
• Researchers at the Wyss Institute at Harvard University, Boston Children's Hospital, and Harvard Medical School developed this technology.

Context

This research represents a significant advancement in drug discovery by leveraging DNA nanoswitches to modulate protein interactions, offering a more efficient screening mechanism for identifying new therapeutic leads compared to traditional binding-based approaches.

Limitations

The evidence is limited to the development and description of the FIND platform by Harvard researchers. Specific performance metrics, validation results, or clinical trial data are not provided in the source material.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 05/11/2026, 20:04:53 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeihkutqledaq2m5fjcm72ijjiklxl4oloojm4vyqjgki6fnjkkxcv4